In the present study, serum albumin and prealbumin levels were significantly higher in the ERAS group than in the control group on postoperative day 7. than in controls (P 0.05). In ERAS patients, serum albumin and prealbumin were higher on postoperative day 7, C-reactive protein was lower on postoperative days 3 and 7, and neutrophil count was lower on postoperative day 3 compared to the values in controls (P 0.05 for all). IgM levels were higher in ERAS patients on postoperative days 3 and 7 (P 0.05), while IgG levels were higher on postoperative day 3 (P 0.05). Total T lymphocytes were higher in ERAS patients on postoperative day 3, while helper T cells and CD4+/CD8+ ratio were higher on postoperative days 3 and 7 (P 0.05 for all). In gastric carcinoma patients, ERAS may reduce perioperative inflammation, improve immunity and postoperative nutrition, shorten hospitalization, and enhance rehabilitation. 0.8290.410ASA grade, n, I/II10/2012/182 = 0.2870.592Tumor stage, n, I/II/III7/12/115/9/162 = 1.6880.430Type of gastrectomy, n2 = 0.3150.854Proximal34Distal1715Total1011Open/laparoscopic resection11/1913/172 = 0.2780.598Operation time, min187.4723.26192.0131.14 0.6400.525Intraoperative blood loss, mL133.3393.21156.4580.02 1.0310.307 Open in a separate window Data are reported as meansSD or number. ERAS: enhanced recovery after surgery; ASA: American Society of Anesthesiologists. Primary endpoint and clinical indicators Postoperative hospital stay was significantly shorter in the ERAS patients than in the control patients (8.893.27 10.76 4.58 days, P=0.039; Table 3). The time to first flatus and defecation, time to removal of drainage tubes, time to resumption of oral feeding, and time to postoperative out-of-bed activities were all significantly shorter in the ERAS patients than in the control patients (Table 3). Table 3 Comparison of postoperative clinical course between the two groups of patients. = 2.1120.039Time to first flatus, days2.631.073.351.32 = 2.3210.024Time to first defecation, days4.253.025.682.36 = 2.0440.045Time to removal of drainage tubes, daysGastric tube1.560.763.221.75 = 4.766 0.01Urinary catheter1.220.993.861.23 = 9.158 0.01Abdominal Quinupristin drainage tube4.471.016.461.95 = 4.963 0.01Time to resumption of oral intake, daysTime to complete transition to liquid diet3.821.815.152.25 = 2.5230.014Time to complete transition to semi-liquid diet5.672.317.213.07 = 2.1950.032Postoperative mobilization, n2 = 15.994 0.01Postoperative day 1152Postoperative day 3910Postoperative complications, n792 = 0.3410.559Mild672 = 0.0980.754Nausea and vomiting32Incision infection12Acute urinary retention21Urinary tract infection02Severe232 = 0.2180.641Gastrointestinal stasis11Anastomotic fistula00Intestinal obstruction12Pulmonary infection00Deep vein thrombosis00 Open in a separate window Data are reported as meansSD or number. When calculating the total number of postoperative complications, if the same patient had two or more complications, it was only recorded as one person, not to repeat the Gfap calculation. ERAS: enhanced recovery after surgery. A total of 8 postoperative complications (in 7 patients) occurred in the ERAS group: nausea and vomiting (n=3), acute urinary retention (n=2), incision infection (n=1), gastrointestinal stasis (n=1), and intestinal obstruction (n=1). One patient had both gastrointestinal emptying dysfunction and acute urinary retention. In the control group, 10 postoperative complications (in 9 patients) occurred: nausea and vomiting (n=2), urinary tract infection (n=2), incision infection (n=2), intestinal obstruction (n=2), acute Quinupristin urinary retention (n=1), and gastrointestinal emptying dysfunction (n=1). One patient had both intestinal obstruction and incision illness. The rates of both slight and severe complications were reduced the ERAS group than in the control group, even though difference was not statistically significant (Table 3). Economic signals Postoperative infusion time (6.42 3.22 days 9.15 3.06 days, P 0.01) and Quinupristin hospital stay (8.893.27 10.76 4.58 days, P=0.039) were significantly shorter in the ERAS group than in the control group. The total hospitalization cost was also reduced the ERAS group than in the control group, but the difference was not statistically significant (US$4800.99681.73 US$5173.89973.50, P 0.05; Table 4). Table 4 Assessment of economic signals between two groups of individuals. = 3.366 0.01Postoperative hospital stay (days)8.893.2710.764.58 = 2.1120.039Hospitalization cost (US$)4800.99681.735173.89973.50 = 1.7190.091 Open in a separate window Data are reported as meansSD. ERAS: enhanced recovery after surgery. Nutritional signals In both organizations, the serum albumin and prealbumin levels in the beginning decreased after surgery and then Quinupristin improved. On postoperative days.